We identified 10 core targets, including SRC, KDR, EGFR, and CASP3, which exhibit high expression levels in AML and are present at relatively elevated concentrations in plasma (Supplementary Figure S1), suggesting their potential as clinical biomarkers. This evidence concerns the gene KDR and acute myeloid leukemia.